Sheri D. Schully, Ph.D.
Knowledge Integration Team Lead, Office of the Associate Director
National Institutes of Health
National Cancer Institute
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
9609 Medical Center Drive, Rm. 4E106, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
telephone: (240) 276-6936
Using the tools of Knowledge Integration to uncover what is known or unknown about cancer epidemiology, translation of genome-based knowledge and technologies to improve population health and the use of biospecimens in research
Ph.D. - Biological Sciences
Louisiana State University
B.S. - Zoology, with a minor in Chemistry
Louisiana State University
Dr. Schully is Team Lead for the Knowledge Integration Team in the Epidemiology and Genomics Research Program's (EGRP) Office of the Associate Director. She was previously a Program Director in EGRP's Host Susceptibility Factors Branch. Dr. Schully's responsibilities include systematically managing the accumulating knowledge base and tools for cancer epidemiology and genomics to accelerate research, evidence-based recommendations, and translation into prevention and clinical practice. In addition, she manages a portfolio of grants related to factors that influence personal susceptibility to cancer, such as genetic and hormonal factors. Dr. Schully is also the Program Officer for the Breast and Colon Cancer Family Registries (CFRs) and Co-Program Officer for the CFR Informatics Support Center.
Dr. Schully coordinates the Trans-NIH Public Health Genomics Interest Group (PHGIG). The PHGIG is leading the Division of Cancer Control and Population Sciences (DCCPS), NCI, and NIH in Public Health Genomics training, workshops, and initiatives with the hope of translating genomic discoveries into actions that reduce the population burden of cancer in the United States. She is also a DCCPS representative to the NCI-wide Biospecimen Coordinating Committee (BCC). The mission of BCC is to coordinate efforts to improve the availability and quality of human specimens needed for research supported by NCI throughout all its programs.
Dr. Schully joined NCI in 2005 as a Presidential Management Fellow through which she completed several rotations in various NCI Divisions and Offices, including with EGRP, the Division of Cancer Epidemiology and Genetics (DCEG), and the Small Business Innovation Research Program within the Office of the Director. During these rotations, Dr. Schully worked with the Cancer Family Registries (CFRs) and organized activities for the Cancer Genetic Markers of Susceptibility Initiative. During her time as a Presidential Management Fellow, Dr. Schully also served as an intern with C-Change, a non-profit organization comprised of the nation's key cancer leaders from government, business, and non-profit sectors.
Schully SD, Benedicto CB, Khoury MJ. How Can We Stimulate Translational Research in Cancer Genomics Beyond Bench to Bedside? Genetics in Medicine. 2012 Jan;14(1):169-70.
Bellcross CA, Bedrosian S, Daniels E, Duquette D, Hampel H, Jasperson K, Joseph DA, Kaye C, Lubin I, Meyer LJ, Reyes M, Scheuner MT, Schully SD, Senter L, Stewart SL, St. Pierre J, Westman J, Wise P, Yang VW, Khoury MJ. Implementing Population-Based Genetic Screening and Cascade Testing for Lynch Syndrome: Summary of a Public Health/Clinical Collaborative Meeting. Genetics in Medicine. 2012 Jan;14(1):152-62.
Khoury MJ, Clauser SB, Freedman AN, Gillanders EM, Glasgow RE, Klein WM, Schully SD. Population Sciences, Translational Research and the Opportunities and Challenges for Genomics to Reduce the Burden of Cancer in the 21st Century. Cancer Epidemiology Biomarkers Prev. 2011 Oct;20(10):2105-14
Ishibe N, Schully SD, Freedman A, Ramsey S. Use of Oncotype DX in Women with Node-Positive Breast Cancer. PLoS Currents: Evidence on Genomic Tests. 2011 Jul 21;3:RRN1249.
Ishibe N, Ramsey S, Carlson J, Freedman A, Schully SD. Use of Epidermal Growth Factor Receptor (EGFR) Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) to Determine Erlotinib Use as First-line Therapy. PLoS Currents: Evidence on Genomic Tests. 2011 Jun 21;3:RRN1245.
Schully SD, Yu W, McCallum V, Benedicto CB, Dong LM, Wulf A, Clyne M, Khoury MJ. Cancer GAMAdb: database of cancer genetic associations from meta-analyses and genome-wide association studies. Eur J Hum Genet. 2011 Apr 13.
Janssens ACJW, Ioannidis JPA, Bedrosian S, Boffetta P, Dolan SM, Dowling N, Fortier I, Freedman AN, Grimshaw JM, Gulcher J, Gwinn M, Hlatky MA, Janes H, Kraft P, Melillo S, O'Donnell CJ, Pencina MJ, Ransohoff D, Schully SD, Seminara D, Winn DM, Wright CF, van Duijn CM, Little J, Khoury MJ. Strengthening the Reporting of Genetic Risk Prediction Studies (GRIPS): Explanation and Elaboration. Eur J Hum Genet. 2011 May;19(5):18 p preceding 494; J Clin Epidemiol. 2011 Mar 10; Eur J Epidemiol. 2011 Apr;26(4):313-37; and Eur J Clin Invest. 2011 Mar 15.
Fabsitz RR, McGuire A, Sharp RR, Hudson K, Pandey M, Biesecker LG, Beskow LM, Bookman E, Burke W, Gonzalez Burchard E, Church G, Clayton EW, Eckfeldt J, Fernandez C, Fisher R, Fullerton SM, Gabriel S, James C, Jarvik G, Kittles R, Leib J, O'Donnell CJ, O'Rourke PP, Rodriguez LL, Romero F, Schully SD, Shuldiner AR, Sze RKF, Thakuria J, Wolf SM, Burke GL. Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group. Circ Cardiovasc Genet. 2010 Dec 1;3(6):574-80.
Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational Research in Cancer Genetics: The Road Less Travelled. Public Health Genomics: 2011;14(1):1-8. Epub 2009 Dec 29.
Khoury MJ, McBride CM, Schully SD, Ioannidis JPA, Feero WG, Janssens AC, Gwinn M et al. The Scientific Foundation for Personal Genomics: Recommendations from an NIH-CDC Multidisciplinary Workshop. Genetics in Medicine: 2009;11(8):559-67.